Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects

Journal of Infectious Diseases

Volumn 204, Issue 10, 2011, Pages 1541-1549

  Baden, Lindsey R ^a   Blattner, William A ^c   Morgan, Cecilia ^f   Huang, Yunda ^g   Defawe, Olivier D ^f   Sobieszczyk, Magdalena E ⁱ   Kochar, Nidhi ^g   Tomaras, Georgia D ^j   Mcelrath, M Juliana ^f   Russell, Nina ^h   Brandariz, Kara ^b   Cardinali, Massimo ^d   Graham, Barney S ^e   Barouch, Dan H ^b   Dolin, Raphael ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Division of AIDS   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Vaccine and Infectious Disease Division   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

ⁱ Columbia University Medical Center ^*  (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; INTERLEUKIN 2;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLASMID; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HIV SERONEGATIVITY; HIV-1; HUMANS; INTERLEUKIN-2; MALE; PLASMIDS; T-LYMPHOCYTES; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; YOUNG ADULT;

EID: 80054752881     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir615     Document Type: Article

References (42)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60. (Pubitemid 28135961)
2. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998; 280:1875-80. (Pubitemid 28299383)
3. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-60. (Pubitemid 44901995)
4. Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25:510-8. (Pubitemid 44856093)
5. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203-12. (Pubitemid 46292224)
6. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
7. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008; 372:1894-905.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
9. Musey L,Hughes J, Schacker T, Shea T, Corey L, McElrathMJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74. (Pubitemid 27461281)
10. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-6. (Pubitemid 28196353)
11. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-60.
12. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189:991-8. (Pubitemid 29149355)
13. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
14. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-50. (Pubitemid 27509814)
15. Eller MA, Eller LA, Opollo MS, et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 2007; 25:7737-42. (Pubitemid 47588523)
16. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-92. (Pubitemid 46616987)
17. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993; 90:4156-60. (Pubitemid 23134185)
18. Shiver JW, Davies ME, Yasutomi Y, et al. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 1997; 15:884-7. (Pubitemid 27287981)
19. Tavel JA, Martin JE, Kelly GG, et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007; 44:601-5. (Pubitemid 46594906)
20. Iwasaki A, Stiernholm BJ, Chan AK, et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158:4591-601. (Pubitemid 127483777)
21. Goujard C, Marcellin F, Hendel-Chavez H, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007; 23:1105-13. (Pubitemid 47571934)
22. Recchia F, Saggio G, Amiconi G, et al. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother 2007; 30:448-54. (Pubitemid 46684434)
23. Middleton M, Hauschild A, Thomson D, et al. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-α2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Ann Oncol 2007; 18:1691-7. (Pubitemid 47506257)
24. Barouch DH, Santra S, Steenbeke TD, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161:1875-82. (Pubitemid 28387609)
25. Barouch DH, Craiu A, Kuroda MJ, et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 2000; 97:4192-7. (Pubitemid 30226109)
26. Dubey S, Clair J, Fu TM, et al. Detection of HIV vaccine-induced cellmediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007; 45:20-7. (Pubitemid 46684439)
27. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 2006; 315:121-32. (Pubitemid 44419512)
28. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54. (Pubitemid 46722712)
29. Shulman N, Bellew M, Snelling G, et al. Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A 2008; 73:847-56.
30. Li F, Malhotra U, Gilbert PB, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006; 24:6893-904. (Pubitemid 46107181)
31. Tomaras GD, Yates NL, Liu P, et al. Initial B cell responses to transmitted human immunodeficiency virus type 1: virion binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63.
32. Liao HX, Sutherland LL, Xia SM, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006; 353:268-82. (Pubitemid 44404137)
33. Moodie Z, Price L, Gouttefangeas C, et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother 2010; 59:1489-501.
34. Agresti A, Coull BA. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 1996; 52:1103-11. (Pubitemid 26296088)
35. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-49. (Pubitemid 44901994)
36. Baden L, Elizaga M, Parker S, et al. Phase I trials of a prophylactic HIV-1 gag vaccine with IL-12 or IL-15 DNA molecular adjuvant (HVTN060 and 063). AIDS Vaccine Meet 2009. In press.
37. Parker S, Elizaga M, Kim D, et al. Phase I trial of a prophylactic HIV-1 gag-pol-env DNA plasmid vaccine with IL-12 or IL-15 DNA molecular adjuvants (HVTN 070). AIDS Vaccine Meet 2010. In press.
38. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-23.
39. Abrams D, Levy Y, Losso MH, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-59.
40. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-8. (Pubitemid 28216581)
41. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6. (Pubitemid 26360453)
42. Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 2004; 22:3092-7. (Pubitemid 39037212)